---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-025941"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:08:10.761915+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibikase receives FDA guidance on 505(b)(2) path for IkT-001Pro; Parkinson's trial enrolling 51 patients

## Summary
- FDA pre-NDA meeting on Jan 19, 2024: acknowledges 505(b)(2) pathway appropriate for IkT-001Pro in blood/gastrointestinal cancers.
- Bioequivalence shows 600mg/800mg IkT-001Pro similar to 400mg/600mg imatinib; FDA advises evaluating doses up to 800mg.
- Company to seek all 11 imatinib indications; must conduct gut transporter studies and use-related risk analysis.
- Risvodetinib 201 Trial: 32 sites open, 51 enrolled, 23 completed 12 weeks, 10 mild/moderate AEs reported.

## SEC filing metadata
- accession: 0001193125-24-025941
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312524025941/0001193125-24-025941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312524025941/d678628d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-025941
- JSON: https://secwatch.observer/filing/0001193125-24-025941.json
- Plain text: https://secwatch.observer/filing/0001193125-24-025941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.